Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The ICF as a framework to collect and interpret data on the extent and variety of disability in neurological conditions.
Dalfampridine in hereditary spastic paraplegia: a prospective, open study.
Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations.
Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1.
Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.
Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation.
Treatment of Acute Relapses in Multiple Sclerosis.
SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells.
Disability in multiple sclerosis: A reference for patients and clinicians.
Sphingosine 1-phosphate receptor agonists: a patent review (2010 - 2012).
Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neuromyelitis Optica.
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Sphingosine-1-phosphate receptors as emerging targets for treatment of pain.
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
Abnormally high levels of anti-collagen type IV IgG antibodies in the serum of patients with a clinically isolated syndrome correlate with an increased risk of conversion to MS.
Event related potential and response time give evidence for a physiological reserve in cognitive functioning in relapsing-remitting multiple sclerosis.
Allogeneic Hematopoietic Stem Cell Transplantation for Neuromyelitis Optica.
Effects of a resistance training program and subsequent detraining on muscle strength and muscle power in multiple sclerosis patients.
Effects of Glatiramer Acetate in a Spontaneous Model of Autoimmune Neuroinflammation.
Street-experienced peripheral B cells traffic to the brain.
Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses.
Evaluation of visual structural and functional factors that predict the development of multiple sclerosis in clinically isolated syndrome patients.
Evaluation of Inner Retinal Layers in Patients with Multiple Sclerosis or Neuromyelitis Optica Using Optical Coherence Tomography.
Environmental factors and their regulation of immunity in multiple sclerosis.
The New Era of Multiple Sclerosis Therapeutics.
Pages
« first
‹ previous
…
315
316
317
318
319
320
321
322
323
…
next ›
last »